title: Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer.
abstract: The aim of this study was to evaluate the role of several biological and histological markers (topoisomerase IIalpha, MIB-1, E2F, apoptotic index, APE/ref-1, p53, Her-2/neu, estrogen and porgesterone receptors, and histological grading) as predictors of pathologic response after anthracycline-based chemotherapy for breast cancer. A series of 50 consecutive breast cancer patients receiving anthracycline-based primary chemotherapy were retrospectively studied. Biological markers were assessed by immunohistochemistry (and by TUNEL assay for apoptotic index) in pre-treatment core biopsies and post-treatment surgical samples. The expression of topoisomerase IIalpha, E2F, MIB-1, estrogen and progesterone receptors decreased, while APE/ref-1 staining increased after treatment. Higher topoisomerase IIalpha (P=0.007) and lower APE/ref-1 (P=0.04) expression were associated with better pathologic response.
authors.affiliation: Medical Oncology Department, University of Udine and S. Maria della Misericordia Hospital, P.le SM della Misericordia, I-33100 Udine, Italy. alessandromarco.minisini@tin.it
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Minisini
authors.forename: Carla
authors.initials: C
authors.lastname: Di Loreto
authors.forename: Mauro
authors.initials: M
authors.lastname: Mansutti
authors.forename: Daria
authors.initials: D
authors.lastname: Artico
authors.forename: Stefano
authors.initials: S
authors.lastname: Pizzolitto
authors.forename: Andrea
authors.initials: A
authors.lastname: Piga
authors.forename: Fabio
authors.initials: F
authors.lastname: Puglisi
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000494:pharmacology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000097:blood*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D002277:Carcinoma / Q000188:drug therapy* / Q000503:physiopathology*; D004260:DNA Repair; D004250:DNA Topoisomerases, Type II / Q000097:blood*; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase / Q000097:blood*; D004268:DNA-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D020287:In Situ Nick-End Labeling; D007527:Isoenzymes; D008875:Middle Aged; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D007527:Isoenzymes; C085108:APEX1 protein, human; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase; D004250:DNA Topoisomerases, Type II